Why is "Non-small-cell lung cancer" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-08-22 20:23:27
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Non-small-cell_lung_cancer entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-08-22 and was most recently seen on 2026-08-22.
Wikipedia Overview
Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is a type of epithelial lung cancer other than small-cell lung cancer (SCLC). Non-small-cell lung cancer accounts for about 85% of all lung cancers. As a class, non-small-cell lung cancers are relatively insensitive to chemotherapy, compared to small-cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy has been used increasingly both preoperatively and postoperatively.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
First-Line Treatment Choices Are Growing More Complex in EGFR-Mutated NSCLC - Oncology News Central
-
Multimodal multitask deep learning for grading management system in non-small cell lung cancer - Nature
-
Younger adults with lung cancer more likely to have targetable genetic changes, study finds - Medical Xpress
-
Dr Salgia on Curing Advanced Non–Small Cell Lung Cancer - Targeted Oncology
-
Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer - AstraZeneca
-
Managing Treatment-Related Toxicities in EGFR-Mutant NSCLC - OncLive
-
How Lung Cancer Spreads: Tracking Metastasis Paths - Everyday Health
-
Non-small cell lung cancer research: advances and persistent challenges - Frontiers
-
First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer - The New England Journal of Medicine
-
Ivonescimab Extends Survival in Advanced Squamous Non-Small Cell Lung Cancer - Cure Today
-
AbbVie's ABBV-1480 Posts 90% Response Rate in Frontline NSCLC Combination - BioPharm International
-
Metastatic Trajectories in Non–Small Cell Lung Cancer Guide Local and Systemic Therapies - ascopubs.org
-
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer - Nature
-
Monitoring Treatment Response in EGFR-Mutant NSCLC - OncLive
-
Single-cell and spatial omics in non-small cell lung cancer: dissecting metabolic reprogramming and tumor-immune ecosystems for precision pharmacology - Frontiers
-
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer - The New England Journal of Medicine
-
Dissecting non-small cell lung cancer (NSCLC) with blood proteomics—from surgical to immunotherapeutic responses - Nature
-
Advances in neoadjuvant immunotherapy for non-small cell lung cancer - Frontiers
-
Label-free pathological subtyping of non-small cell lung cancer using deep classification and virtual immunohistochemical staining - Nature
-
Can evolutionary therapy be applied in non-small cell lung cancer? - Nature
-
AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline - Yahoo Finance
-
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial - Nature
-
Taletrectinib and Brain Metastases in Non–Small Cell Lung Cancer - Targeted Oncology
-
Dr Skoulidis on First-Line Divarasib Plus Pembrolizumab in KRAS G12C+ NSCLC - OncLive
-
AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline - Investing News Network
-
Life After Stage 3B Non-Small Cell Lung Cancer - Cure Today
-
Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026 - us.acrofan.com
-
Machine learning–based prediction of recurrence after curative resection in non–small cell lung cancer - Nature
-
KRAS G12d-Targeted Setidegrasib Shows Activity in Non–Small Cell Lung Cancer - Cure Today
-
Future Directions and Unmet Needs in EGFR Mutated Metastatic Non-Small Cell Lung Cancer - CancerNetwork
-
Defining the abscopal effect in non-small cell lung cancer in the era of immunotherapy and lung ablation treatment: a narrative review - Frontiers
-
Frontline Treatment Selection in EGFR-Mutated Non-Small Cell Lung Cancer: Monotherapy Versus Combination Strategies - OncLive
-
Key Updates in Non-Small Cell Lung Cancer From ASCO 2026 - Medscape
-
FDA Approves Hernexeos for HER2-Mutant Non-Small Cell Lung Cancer - Cure Today
-
A Postpartum Symptom No One Expected: Non-Small Cell Lung Cancer - Yale Medicine
-
When Standard Therapy Is Not Feasible in Stage III Non–Small Cell Lung Cancer - HMP Global Learning Network
-
Research progress of small molecule targeted drugs for non-small cell lung cancer - Frontiers
-
Few Breakthroughs and Big Questions in Stage III NSCLC - Oncology News Central
-
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations - Nature
-
Brain metastasis from non-small cell lung cancer: crosstalk between cancer cells and tumor microenvironment components - Nature
-
An evolving landscape: predictive and therapeutic biomarkers in advanced non-small cell lung cancer - Frontiers
-
Metastatic Non-Small Cell Lung Cancer to the... : American Journal of Gastroenterology - Lippincott Home
-
Estimating major pathological response in non-small cell lung cancer patients with post-neoadjuvant therapy using MMT-net - Nature
-
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial - The Lancet
-
Selecting Combination Versus Monotherapy in EGFR Mutated Metastatic Non-Small Cell Lung Cancer - CancerNetwork
-
Evolving treatment strategies for HER2-altered non–small-cell lung cancer: the rise of TKIs and ADCs - Frontiers
-
Natural compounds for non-small cell lung cancer treatment: focus on the EGFR signaling pathway - Frontiers
-
Clinical response in advanced non-small cell lung cancer with high PD-L1 expression and MET exon 14 skipping mutation: a case analysis of overcoming immunotherapy resistance and literature review - Frontiers
-
Molecular Profiling Nuances in ROS1-Positive Non-Small Cell Lung Cancer: PD-L1, TMB, and Testing Workflow - Targeted Oncology
-
Integrating cryoablation with immunotherapy in non-small cell lung cancer: mechanisms, clinical evidence, and translational barriers - Frontiers
-
KEYNOTE-671: Five-Year Data Confirm Durable Benefit of Perioperative Pembrolizumab in Early-Stage NSCLC - Oncodaily
-
Breaking Treatment Barriers: Therapy for Advanced (Metastatic) EGFR-Mutated Non-Small Cell Lung Cancer After Targeted Therapy and Chemotherapy - OncLive
-
Non-small cell lung cancer after EGFR-TKI resistance: from drug resistance mechanisms to precision interventions - Frontiers
-
ROS1 -positive non-small cell lung cancer: from genomics to treatment decisions - Frontiers
-
Stage 3B Non-Small Cell Lung Cancer Treatments and Prognosis - Verywell Health
-
Application of deep learning in prognostic prediction of non-small cell lung cancer - Frontiers
-
I Just Got Diagnosed With Non-Small-Cell Lung Cancer. Now What? - WebMD
-
Pfizer announces phase 3 results for potential non-small cell lung cancer treatment - PMLiVE
-
How Can You Lower Your Risk of Non-Small Cell Lung Cancer? - health.com
-
Surgical outcomes and quality of life in octogenarians with early-stage non-small cell lung cancer: a prospective cohort study - The Lancet
-
Editorial: Liquid biopsy in non-small cell lung cancer for diagnosis, treatment selection and monitoring - Frontiers
-
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer - The New England Journal of Medicine
-
Long-term survival in a patient with non-small cell lung cancer harboring KRAS G13C and TP53 co-mutations: case report and literature review - Frontiers
-
Pharmacists Navigate an Evolving Immunotherapy Landscape in Advanced Non–Small Cell Lung Cancer - Pharmacy Times
-
Enhancing Non-small Cell Lung Cancer Susceptibility to Anti-PD-1/PD-L1 Therapy through PD-L1 Ligand–Ir(III) Complex Conjugates - Science Partner Journals
-
Clinical Case 2: ROS1-Positive Advanced Non-Small Cell Lung Cancer with Progression on First-Line Therapy and Solvent-Front Resistance - Targeted Oncology
-
Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancer - Nature
-
Biomarker Testing in Patients with Metastatic Non-small Cell Lung Cancer (NSCLC) - Targeted Oncology
-
CSPC Advances Chemo-Free ADC Combo In 1L NSCLC - insights.citeline.com
-
Unresectable stage III non-small-cell lung cancer: state of the art and challenges - Nature
-
Do the "oldest old" non-small cell lung cancer patients experience the worst outcomes after radiotherapy? - European Society of Medicine
-
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China - The Lancet
-
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - Yahoo Finance
-
Robotic Versus Video-Assisted Thoracic Surgery for Non-Small Cell Lung Cancer: A Systematic Review - Cureus
-
The Role of TROP2 in Non-Small Cell Lung Cancer - OncLive
-
Targetable driver gene–tumor immune microenvironment axis in non-small cell lung cancer: from molecular pathological mechanisms to precision immunotherapy stratification strategies - Frontiers
-
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration - The Lancet
-
Sevabertinib Yields Antitumor Activity in Non–Small Cell Lung Cancer - Targeted Oncology
-
Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated Non-Small Cell Lung Cancer - Cure Today
-
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration - The Lancet
-
Case Report: Complete pathologic response to neoadjuvant immunotherapy-chemotherapy in a patient with RET fusion-positive non-small cell lung cancer - Frontiers
-
FAK co-inhibition in KRASG12C-mutated non-small-cell lung cancer - The Lancet
-
Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab - Yahoo Finance
-
Rezivertinib in EGFR -Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study - Science Partner Journals
-
Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study - OncLive
-
-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial - The Lancet
-
Amtagvi Prompts Responses in Non–Small Cell Lung Cancer - Cure Today
-
Syndrome of Inappropriate Anti-diuretic Hormone (SIADH) in Non-small Cell Lung Cancer (NSCLC) Following Agent Orange Exposure: A Case Report - Cureus
-
Role of Novel Bispecific Antibodies and Immunotherapy in Non–Small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations - ascopubs.org
-
Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer - Nature
-
Non-Small Cell Lung Cancer (NSCLC) Global Market Trends and - GlobeNewswire
-
AbbVie reveals promising lung cancer drug data at 2026 World Conference on Lung Cancer. - Pluang
-
Amivantamab for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer - Pharmacy Times
-
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial - The Lancet
-
Cullinan's lung cancer trial met its main goal; results are set for presentation in September - Stock Titan
-
BioNTech's lung cancer program has 16 ongoing trials, with new data due in Seoul - Stock Titan
-
Saved by the Speed of Science: Michelle’s Story - City of Hope
-
AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline - marketscreener.com
-
PTGFRN promotes non-small cell lung cancer malignant progression and reprograms BCAA metabolism by activating STAT3/BCAT1 pathway - ScienceDirect.com
-
SABR Ties SOC Surgery in Non-Small Cell Lung Cancer Survival - Medscape
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.